CAMBRIDGE, Mass., Jan. 10, 2025 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today announced the U.S. Food and Drug Administration (FDA) recently granted an additional Fast Track designation to XMT-1660.…
Tue, 06 May 2025 09:16:00 GMT Bluebird urged shareholders to back a take-private deal that could close imminently. Elsewhere, Unity Biotechnology began a strategic review and Mersana announced plans to cut more than half its ...
Tue, 06 May 2025 06:40:00 GMT Mersana Therapeutics only has eyes for Emi-Le. Seeking to extend its cash runway into mid-2026, the biotech is laying off 55% of its employees and cutting back internal R&D work to focus on lead ...
Tue, 06 May 2025 05:22:00 GMT Cost-saving initiatives expected to extend company's cash runway and support current operating plan commitments into mid-2026
Tue, 06 May 2025 04:15:00 GMT Mersana Therapeutics, Inc. announced a strategic ... Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may ...
Tue, 06 May 2025 04:00:00 GMT Source: Mersana Therapeutics, Inc. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. Sign up for our newsletter ...
